Ustekinumab trough concentration affects clinical and endoscopic outcomes in patients with refractory Crohn’s disease: a Chinese real-world study

Ustekinumab trough concentration affects clinical and endoscopic outcomes in patients with refractory Crohn’s disease: a Chinese real-world study

Abstract Background Ustekinumab (UST), a newly-used biologic targeting p40 subunit of IL12 and IL23 in China, exerts a confirmed therapeutic effect on the induction and maintenance therapies for refractory Crohn’s disease (CD). Therapeutic drug monitoring based on trough and antibody concentration i...

Full description

Bibliographic Details
Main Authors: Jia-yin Yao, Min Zhang, Wei Wang, Xiang Peng, Jun-zhang Zhao, Tao Liu, Zhi-wei Li, Hai-tian Sun, Pinjin Hu, Min Zhi
Format: Article
Language:English
Published: BMC 2021-10-01
Series:BMC Gastroenterology
Subjects:
Crohn’s disease
Ustekinumab
Trough concentration
Clinical remission
Endoscopic remission
Therapeutic drug monitoring
Online Access:https://doi.org/10.1186/s12876-021-01946-8

Internet

https://doi.org/10.1186/s12876-021-01946-8

Similar Items